Literature DB >> 16940139

Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.

Marcus J P Geist, Gerlinde Egerer, Jürgen Burhenne, Gerd Mikus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940139      PMCID： PMC1563530          DOI： 10.1128/AAC.00551-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  10 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population.

Authors:  Maria Burian; Sabine Grösch; Irmgard Tegeder; Gerd Geisslinger
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

3.  Development and validation of a high-performance liquid chromatography assay for voriconazole.

Authors:  Gennethel J Pennick; Martin Clark; Deanna A Sutton; Michael G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

4.  Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19.

Authors:  Takako Shimizu; Hirohide Ochiai; Fredrik Asell; Hiroshi Shimizu; Ryuta Saitoh; Yoshimasa Hama; Jun Katada; Munehiro Hashimoto; Hitoshi Matsui; Katsuhiko Taki; Tsuguchika Kaminuma; Michiko Yamamoto; Yoshitaka Aida; Akira Ohashi; Naoki Ozawa
Journal:  Drug Metab Pharmacokinet       Date:  2003       Impact factor: 3.614

Review 5.  Drug metabolism and variability among patients in drug response.

Authors:  Grant R Wilkinson
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

6.  Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.

Authors:  Jens Rengelshausen; Maria Banfield; Klaus-Dieter Riedel; Jürgen Burhenne; Johanna Weiss; Torben Thomsen; Ingeborg Walter-Sack; Walter E Haefeli; Gerd Mikus
Journal:  Clin Pharmacol Ther       Date:  2005-07       Impact factor: 6.875

7.  Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.

Authors:  Gerd Mikus; Verena Schöwel; Magdalena Drzewinska; Jens Rengelshausen; Reinhard Ding; Klaus-Dieter Riedel; Jürgen Burhenne; Johanna Weiss; Torben Thomsen; Walter E Haefeli
Journal:  Clin Pharmacol Ther       Date:  2006-07-03       Impact factor: 6.875

Review 8.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Authors:  Craig R Lee; Joyce A Goldstein; John A Pieper
Journal:  Pharmacogenetics       Date:  2002-04

9.  Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors:  L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

Authors:  R Hyland; B C Jones; D A Smith
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922
  10 in total
  13 in total

1.  Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Authors:  Maud Berge; Romain Guillemain; David A Trégouet; Catherine Amrein; Veronique Boussaud; Patrick Chevalier; Agnes Lillo-Lelouet; Christine Le Beller; Pierre Laurent-Puig; Philippe H Beaune; Eliane M Billaud; Marie-Anne Loriot
Journal:  Eur J Clin Pharmacol       Date:  2010-10-31       Impact factor: 2.953

2.  Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications.

Authors:  Marcus J P Geist; Gerlinde Egerer; Jürgen Burhenne; Klaus-Dieter Riedel; Gerd Mikus
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

3.  The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Guo Wang; He-Ping Lei; Zhi Li; Zhi-Rong Tan; Dong Guo; Lan Fan; Yao Chen; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2008-11-04       Impact factor: 2.953

4.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

5.  PharmGKB summary: voriconazole pathway, pharmacokinetics.

Authors:  Julia M Barbarino; Aniwaa Owusu Obeng; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

6.  The Impact of Model-Misspecification on Model Based Personalised Dosing.

Authors:  David A J McDougall; Jennifer Martin; E Geoffrey Playford; Bruce Green
Journal:  AAPS J       Date:  2016-06-15       Impact factor: 4.009

7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Authors:  B Moriyama; A Owusu Obeng; J Barbarino; S R Penzak; S A Henning; S A Scott; Jag Agúndez; J R Wingard; H L McLeod; T E Klein; S J Cross; K E Caudle; T J Walsh
Journal:  Clin Pharmacol Ther       Date:  2017-04-18       Impact factor: 6.875

8.  Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.

Authors:  H-R He; J-Y Sun; X-D Ren; T-T Wang; Y-J Zhai; S-Y Chen; Y-L Dong; J Lu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267

9.  Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders.

Authors:  Koki Ueda; Yasuhito Nannya; Keiki Kumano; Akira Hangaishi; Tsuyoshi Takahashi; Yoichi Imai; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2009-04-02       Impact factor: 2.490

Review 10.  CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?

Authors:  Aniwaa Owusu Obeng; Eric F Egelund; Abdullah Alsultan; Charles A Peloquin; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2014-02-07       Impact factor: 4.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.